Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naive subjects with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naive subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 4
  • Sponsors Novo Nordisk

Most Recent Events

  • 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 07 Jun 2022 Results from the SURPASS-2 trial and SUSTAIN-4, comparing the 5-year risk of diabetes complications of tirzepatide (TZP) and semaglutide with insulin glargine, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
  • 29 Jun 2021 Results of post-hoc analysis of SUSTAIN1-5 & 7-10 presented at the 81st Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top